What Ozempic Is and How It Works
Ozempic is a brand name for semaglutide, a glucagon-like peptide-1 receptor agonist developed by Novo Nordisk and approved by the U.S. Food and Drug Administration for type 2 diabetes and chronic weight management. The drug mimics the hormone GLP-1, which helps regulate blood sugar, appetite, and gastric emptying. Semaglutide is a peptide, not a steroid or thyroid hormone, so it does not directly alter estrogen, testosterone, or cortisol pathways.
In clinical trials, semaglutide lowered HbA1c and supported weight loss by slowing gastric emptying and reducing appetite via brain receptors. The FDA approved Ozempic for type 2 diabetes in 2017, and later approved Wegovy, a higher-dose semaglutide product, for chronic weight management. Novo Nordisk remains the primary manufacturer, and the company reports strong global demand for both products.
How Ozempic Interacts With Hormones
GLP-1, Insulin, and Glucagon
Ozempic activates GLP-1 receptors on pancreatic beta cells, which increases insulin release when blood sugar is high and suppresses glucagon secretion. This hormone-level change improves glucose control without stimulating insulin when levels are low, lowering the risk of hypoglycemia. The FDA label notes that semaglutide is not a substitute for insulin and does not replace the body's natural insulin production.
Thyroid and Calcitonin
Animal studies showed semaglutide caused thyroid C-cell tumors in rodents, leading the FDA to require a boxed warning about medullary thyroid carcinoma risk in patients with a personal or family history of certain genetic syndromes. Human data have not confirmed a similar cancer risk, but the label advises monitoring calcitonin levels and thyroid nodules. Patients should discuss thyroid screening with their prescriber, especially if they have relevant family history.
Gut Hormones and Appetite Signals
Ozempic slows gastric emptying and affects gut hormones such as ghrelin, which influences hunger. Clinical data show reductions in appetite and food preference, which contribute to weight loss. These changes are mediated through central nervous system GLP-1 receptors rather than direct steroid or sex-hormone pathways.
Clinical Data, Regulatory Status, and Practical Considerations
Novo Nordisk has published extensive trial data, including the SUSTAIN and STEP programs, showing improvements in HbA1c, body weight, and cardiovascular outcomes. The FDA label includes warnings for pancreatitis, gallbladder problems, acute kidney injury, and diabetic retinopathy. Common side effects include nausea, vomiting, diarrhea, and constipation, which are linked to delayed gastric emptying rather than direct hormonal disruption.
Prescribers use Ozempic as part of a broader treatment plan that includes diet, exercise, and monitoring of diabetes-related hormones such as insulin and HbA1c. Patients should report symptoms such as severe abdominal pain, changes in urination, or vision problems, and should not stop or change doses without medical guidance. The FDA and Novo Nordisk provide current prescribing information and safety updates on their official websites.
Forbes has reported on the commercial performance and market impact of Novo Nordisk's GLP-1 products. The FDA website provides the official Ozempic prescribing information, including the boxed warning and detailed safety data.